CCND1 amplification was therefore defined as a CCND1 probe to CEP11 ratio of 2.0 or greater—the same ratio recommended by the U.S. Food and Drug Administration for HER2 amplification diagnosis for breast cancer [26]. Here, ERBB2 is linked to breast carcinoma.